Publication: Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs
Authors: Kirsten Boerngen, Yogini Patel, Melissa Pittorino and Céline E. Toutain
Published: 2026, volume 49, issue 1, pages 7–16.
Location: Two laboratory experiments in Australia; one in the United States.
Funding: Elanco Animal Health. All authors were company employees.
Key Definitions:
- Pharmacokinetics: How a drug enters, moves through and leaves the body.
- Dose: The amount of drug administered.
- Exposure: Drug concentrations in the blood plasma over time.
- Janus kinase (JAK) inhibitor: A medicine that blocks certain signals involved in inflammation and itching.
- Bioavailability: The proportion of a dose that reaches the bloodstream.
- Target animal safety study: A study in the species a medicine is intended for, usually in healthy animals, giving the medicine at multiples of the intended dose to identify safety problems.
The Study
Three laboratory experiments used groups of 16, 25 and 24 beagles (65 dogs in total, unless any were reused; the paper does not say) to investigate ilunocitinib, a medicine to treat allergic skin disease in dogs. Procedures included overnight fasting of at least 16 hours, oral dosing, intravenous injections and repeated blood sampling, with up to 16 blood samples over 72 hours after an intravenous dose. Some dogs received a single dose of five times the maximum therapeutic dose (five fasted and eight fed dogs) to see how much drug reached the bloodstream at higher doses. Repeated daily dosing, for 11 days in five dogs, was only at the maximum therapeutic dose of 0.8 mg/kg.
These experiments examined how administration of the drug, food, dose size and repeated dosing affect drug exposure. They did not test whether the medicine reduced itching or skin lesions in the laboratory beagles. The paper does not report that these dogs had skin disease or describe their fate afterwards. Separate studies in the same development programme, not reported in this article, are described by the UK Veterinary Medicines Directorate as using models of induced itching and skin lesions.
Higher doses increased exposure less than proportionally, meaning giving five times the usual maximum dose didn’t mean five times as much drug reached the bloodstream. In both fed and fasted dogs, a fivefold dose gave roughly double the exposure. Food increased absorption of the drug (80% bioavailability when fed, 61% when fasted), although the authors judged the difference not clinically relevant in the field trials. Repeated dosing for 11 days in five dogs produced little accumulation in most; one dog had a markedly higher accumulation ratio, which the authors described as an isolated incident.
The article also analysed blood-concentration data from separate clinical trials in client-owned dogs with allergic or atopic skin disease (sampled on two study days). Evidence of the drug’s effectiveness came from those separate pieces of research. The authors acknowledge these trials were not designed to assess pharmacokinetics.
Ethical Considerations
There is value in research that improves veterinary treatments, particularly when the research is intended to benefit the very species being used. In this case, the experiments provided useful information about how ilunocitinib is absorbed, how food and different doses affect drug exposure, and whether the drug accumulates with repeated use. These findings helped inform appropriate dosing and subsequent safety studies.
Veterinary medicines undergo separate assessments of safety and effectiveness. Safety studies are often conducted in healthy animals to identify potential adverse effects, including at doses higher than those recommended for treatment. Effectiveness studies, on the other hand, investigate whether the medicine works in animals with the condition it is intended to treat. This helps explain why healthy laboratory beagles were used in this research.
The researchers also took some steps to reduce animal numbers, including a crossover design where the same dogs were tested under fed and fasted conditions.
However, there is an interesting ethical consideration here. Unlike research that uses animals to develop treatments for humans, this research was conducted in the very species it intends to benefit. While the findings may help improve treatment for dogs with allergic skin disease, the individual beagles involved were not receiving treatment for an existing condition and had no apparent direct therapeutic benefit.
There is some similarity here with human clinical trials, where healthy volunteers may be used to investigate how a medicine behaves in the body. One important difference, however, is that humans can ordinarily provide informed consent, whereas animals cannot. This makes it particularly important to consider how the research is conducted and whether the use of animals is justified. Therefore, whilst the research generated useful information, it is still worth asking whether the same information could have been obtained using fewer dogs or through a different research design.
For example, the article also analysed blood samples collected during clinical trials involving client-owned dogs with allergic skin disease. Although these trials were not specifically designed to investigate pharmacokinetics, they show that some information about how the drug behaves in the body can be gathered alongside research investigating treatment outcomes. Could some of the pharmacokinetic experiments have been incorporated into these existing studies, rather than conducted separately?
Of course, certain procedures, such as intravenous dosing or administering doses above the recommended treatment range, may not be appropriate for dogs already receiving treatment. This means clinical trials may be suitable for answering some questions, but not necessarily all of them.
Our thoughts..
From AFSA’s perspective, the question is not whether the research had value, but whether all three experiments were necessary, whether fewer dogs could have been used, and whether existing evidence, non-animal methods or less harmful approaches could have provided some of the information. Acknowledging the benefits of this research does not mean these questions should be overlooked. It rather encourages us to consider how veterinary research can continue to improve treatments while also reducing the number of animals used wherever possible.
Alternatives
Existing evidence, non-animal laboratory methods and computer modelling should be considered before undertaking further animal experiments. The European Medicines Agency’s draft reflection paper says in vitro and computer-based approaches to replace or reduce pharmacokinetic animal studies should be considered case by case, with their validity demonstrated. No regulator accepting such methods in place of target-species studies for a new active substance was identified in the sources reviewed. Where scientifically appropriate, clinical research involving dogs already receiving treatment may provide relevant information without creating a separate population of laboratory subjects. This would mean fewer dogs held as laboratory subjects, in alignment with the 3Rs.
Conclusion
This research provided information relevant to drug administration and the drug in the trails does offer potential benefit for dogs suffering from skin infections, particularly those whose symptoms aren’t adequately controlled by existing treatments. The research highlights the need for investment in the development of alternatives to animals in pharmacological safety studies and reinforces the importance of refinement and reduction in the interim.